IFNA17 and cancer: CpG-C (such as CpG 2395 or ODN 2395), which combine the effects of CpG-A and CpG-B, are potent inducers of IFN-α from pDC and strong B cell activators, proving to be more powerful adjuvant in cancer vaccine development [21–24].